BREAKING
Earnings Summary: A snapshot of Duke Energy’s Q4 2025 report 5 hours ago Fiserv (FISV) Earnings: 4Q25 Key Numbers 7 hours ago CVS Health (CVS) Q4 2025 revenue rises 8%; adjusted earnings decline 8 hours ago Chegg Q4 2025 Earnings Soar: New Strategy Stuns Market 20 hours ago PAL Q4 2025 Earnings Explode: Mergers Pay Off Now 20 hours ago Outdoor Holding Company Q3 2026 Earnings Soar 7% 23 hours ago Apollo Q4 2025 Earnings Rocket: Historic AUM Breakthrough 1 day ago Anavex Q1 2026 Earnings Rise: Breakthrough Drug Nears 1 day ago Dynatrace Shares Rise After Q3 Fiscal 2026 Results Beat Guidance 1 day ago Eli Lilly and Company (LLY) to acquire Orna Therapeutics 1 day ago Earnings Summary: A snapshot of Duke Energy’s Q4 2025 report 5 hours ago Fiserv (FISV) Earnings: 4Q25 Key Numbers 7 hours ago CVS Health (CVS) Q4 2025 revenue rises 8%; adjusted earnings decline 8 hours ago Chegg Q4 2025 Earnings Soar: New Strategy Stuns Market 20 hours ago PAL Q4 2025 Earnings Explode: Mergers Pay Off Now 20 hours ago Outdoor Holding Company Q3 2026 Earnings Soar 7% 23 hours ago Apollo Q4 2025 Earnings Rocket: Historic AUM Breakthrough 1 day ago Anavex Q1 2026 Earnings Rise: Breakthrough Drug Nears 1 day ago Dynatrace Shares Rise After Q3 Fiscal 2026 Results Beat Guidance 1 day ago Eli Lilly and Company (LLY) to acquire Orna Therapeutics 1 day ago
ADVERTISEMENT
AlphaGraphs

Johnson & Johnson (JNJ) Q3 2024 Earnings: Key financials and quarterly highlights

Johnson & Johnson (NYSE: JNJ) reported its third quarter 2024 earnings results today. Reported sales increased 5.2% year-over-year to $22.5 billion. GAAP earnings decreased 37.5% to $2.7 billion while EPS fell 34% to $1.11 compared to last year. Adjusted EPS was down 9% to $2.42. Revenue and earnings beat expectations. For full-year 2024, JNJ expects reported […]

$JNJ October 15, 2024 1 min read

Johnson & Johnson (NYSE: JNJ) reported its third quarter 2024 earnings results today.

Reported sales increased 5.2% year-over-year to $22.5 billion.

GAAP earnings decreased 37.5% to $2.7 billion while EPS fell 34% to $1.11 compared to last year. Adjusted EPS was down 9% to $2.42.

Revenue and earnings beat expectations.

For full-year 2024, JNJ expects reported sales of $88.4-88.8 billion and adjusted EPS of $9.88-9.98.

ADVERTISEMENT

The stock was down 1% in premarket hours on Tuesday.

Prior performance

ADVERTISEMENT